Solventum vs Teleflex
SOLV and TFX side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How SOLV and TFX compare
Solventum is the larger company, worth 2.3 times as much as Teleflex ($13.8B against $5.9B).
Teleflex grew revenue faster over the last twelve months (30.7% versus −0.93% for Solventum).
Solventum keeps more of each dollar of sales as profit, with a net margin of 17.3% compared with −45.8% at Teleflex.
Teleflex pays a dividend yielding 0.97%; Solventum does not pay one.
Solventum scores higher on the StockData Score (14 against 7 for Teleflex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | SOLV | TFX |
|---|---|---|
| Size and price | ||
| Market cap | $13.8B | $5.9B |
| Share price | $81.33 | $139.77 |
| Change, 1 year | 16.6% | 9.1% |
| Change, 5 years | – | −60.4% |
| Beta (5Y) | 0.58 | 0.85 |
| Employees | 10K | 16K |
| StockData Score | ||
| Total score | 14 (better) | 7 |
| Valuation score | 6 (better) | 1 |
| Growth score | 2 (better) | 1 |
| Performance score | 5 (better) | 1 |
| Health score | 1 | 1 |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | 9.9× | – |
| P/S | 1.7× (better) | 2.6× |
| P/B | 2.9× | 2.0× (better) |
| EV/EBITDA | 7.2× (better) | 43.7× |
| P/FCF | – | 35.2× |
| PEG | 2.21 | – |
| FCF yield | −0.85% | 2.8% (better) |
| Fair value | $185.43 | $36.02 |
| Margin of safety | 56.1% (better) | −288% |
| Growth | ||
| Revenue growth (TTM) | −0.93% | 30.7% (better) |
| Revenue growth, 5Y average | – | −4.7% |
| Net income growth (TTM) | 277% (better) | −638% |
| EPS growth (TTM) | 277% (better) | −645% |
| Profitability | ||
| Gross margin | 54.7% | 54.9% (better) |
| Operating margin | 25.0% (better) | 2.0% |
| Net margin | 17.3% (better) | −45.8% |
| FCF margin | −1.4% | 7.5% (better) |
| Return on equity | 34.0% (better) | −28.9% |
| Return on invested capital | 17.2% (better) | 0.62% |
| Financial health | ||
| Debt / equity | 1.06 | 0.97 (better) |
| Net debt / EBITDA | 1.81 (better) | 13.01 |
| Interest coverage | – | 0.4× |
| Current ratio | 1.02 | 2.60 (better) |
| Altman Z-score | 2.14 (better) | 1.47 |
| Piotroski F-score | 5 | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.97% |
| Years of dividend growth | – | 0 |
| Dividend growth, 5Y average | – | 0.00% |
| Buyback yield | – | 4.2% |
| Shareholder yield | 0.00% | 5.2% (better) |
| Ownership | ||
| Held by institutions | 75.0% | 113% |
| Held by insiders | 30.3% | 0.73% |
| Insider net buying, 12 months | $100K | – |
| Superinvestors holding | 2 (better) | 1 |
| Short interest, % of float | 4.1% | 9.6% |
Go deeper
- SOLV stock overview
- SOLV income statement
- SOLV valuation and score
- TFX stock overview
- TFX income statement
- TFX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.